Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bretylate
2. Bretylium Tosilate
3. Bretylol
4. Ornid
1. 61-75-6
2. Bretylol
3. Bretylium Tosilate
4. Bretylate
5. Ornid
6. Darenthin
7. N-(2-bromobenzyl)-n,n-dimethylethanaminium 4-methylbenzenesulfonate
8. Darentin
9. Bretylan
10. Bretylium (tosylate)
11. Bretylium P-toluenesulfonate
12. Asl-603
13. Bretylii Tosilas
14. Tosilato De Bretilio
15. Tosilate De Bretylium
16. (o-bromobenzyl)ethyldimethylammonium P-toluenesulfonate
17. Nsc-62164
18. Bretylium Tosilate [inn]
19. 2-bromo-n-ethyl-n,n-dimethylbenzenemethanaminium 4-methylbenzenesulfonate
20. Dimethylethyl-o-bromobenzylammonium-p-toluenesulphonate
21. N-ethyl-n-o-bromobenzyl-n,n-dimethylammonium Tosylate
22. Benzenemethanaminium, 2-bromo-n-ethyl-n,n-dimethyl-, Salt With 4-methylbenzenesulfonic Acid (1:1)
23. Mls000028635
24. Chebi:3173
25. 78zp3yr353
26. Cas-61-75-6
27. Ncgc00016119-02
28. Asl 603
29. Smr000058647
30. Bretylium Tosilate (inn)
31. Bretilio Tosilato
32. Bretilio Tosilato [dcit]
33. Nsc 62164
34. Bretylii Tosilas [inn-latin]
35. Nsc62164
36. Bretylium Tosylate In Dextrose 5%
37. Sr-01000000254
38. Tosilate De Bretylium [inn-french]
39. Tosilato De Bretilio [inn-spanish]
40. Einecs 200-516-8
41. Bretylium Tosylate (usp)
42. Bretylium Tosylate In Plastic Container
43. Unii-78zp3yr353
44. Bretylium Tosylate [usan:usp]
45. Bretyliume Tosylate
46. Bretylol (tn)
47. Bretylium Tosylate In Dextrose 5% In Plastic Container
48. Opera_id_1513
49. Lopac-b-8406
50. Dsstox_cid_2685
51. Benzenemethanaminium, 2-bromo-n-ethyl-n,n-dimethyl-, Salt With 4-methylbenzenesulfonic Acid
52. Dsstox_rid_76691
53. Dsstox_gsid_22685
54. Schembl40898
55. Bretylium Tosylate [mi]
56. Chembl1095292
57. Dtxsid1022685
58. Bretylium Tosylate [usan]
59. Bretylium Tosylate [vandf]
60. Hms1570n06
61. Hms2097n06
62. Hms2235i21
63. Hms3714n06
64. Bretylium Tosilate [mart.]
65. Ammonium, (o-bromobenzyl)ethyldimethyl-, P-toluenesulfonate
66. Bretylium Tosilate [who-dd]
67. Bretylium Tosylate [usp-rs]
68. Tox21_110308
69. (2-bromophenyl)methyl-ethyl-dimethylazanium;4-methylbenzenesulfonate
70. Hy-12961a
71. Mfcd00038731
72. Akos015842525
73. Ccg-204319
74. Cs-5728
75. Bretylium Tosylate [orange Book]
76. Ncgc00016119-01
77. Ncgc00016119-03
78. Ncgc00016119-04
79. Ncgc00024457-02
80. As-56957
81. Bretylium Tosylate [usp Monograph]
82. Wln: Er B1k2&1&1 &oswr D1
83. Bretylium Tosylate, >99% (tlc), Powder
84. (2-bromobenzyl)ethyldimethylammonium Tosylate
85. Eu-0100224
86. Ft-0603258
87. B 8406
88. D00645
89. Sr-01000000254-2
90. Sr-01000000254-5
91. Q27105972
92. (2-bromobenzyl)ethyldimethylammonium Toluene-4-sulfonate
93. (o-bromobenzyl)ethyldimethylammonium P-toluenesulphonate
94. N-(2-bromobenzyl)-n,n-dimethylethanaminium4-methylbenzenesulfonate
95. [(2-bromophenyl)methyl](ethyl)dimethylazanium 4-methylbenzene-1-sulfonate
96. 2-bromo-n-ethyl-n,n-dimethylbenzenemethanaminium 4-methyl-benzenesulfontate
97. Bretylium Tosylate, United States Pharmacopeia (usp) Reference Standard
98. N-[(2-bromophenyl)methyl]-n,n-dimethylethanaminium 4-methylbenzenesulfonate
99. Benzenemethanaminium,n-dimethyl-, Salt With 4-methylbenzenesulfonic Acid (1:1)
Molecular Weight | 414.4 g/mol |
---|---|
Molecular Formula | C18H24BrNO3S |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 3 |
Exact Mass | 413.06603 g/mol |
Monoisotopic Mass | 413.06603 g/mol |
Topological Polar Surface Area | 65.6 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 349 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Adrenergic Antagonists
Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE. (See all compounds classified as Adrenergic Antagonists.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
C - Cardiovascular system
C01 - Cardiac therapy
C01B - Antiarrhythmics, class i and iii
C01BD - Antiarrhythmics, class iii
C01BD02 - Bretylium tosilate
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Bretylium Tosylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bretylium Tosylate, including repackagers and relabelers. The FDA regulates Bretylium Tosylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bretylium Tosylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bretylium Tosylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bretylium Tosylate supplier is an individual or a company that provides Bretylium Tosylate active pharmaceutical ingredient (API) or Bretylium Tosylate finished formulations upon request. The Bretylium Tosylate suppliers may include Bretylium Tosylate API manufacturers, exporters, distributors and traders.
click here to find a list of Bretylium Tosylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Bretylium Tosylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Bretylium Tosylate active pharmaceutical ingredient (API) in detail. Different forms of Bretylium Tosylate DMFs exist exist since differing nations have different regulations, such as Bretylium Tosylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bretylium Tosylate DMF submitted to regulatory agencies in the US is known as a USDMF. Bretylium Tosylate USDMF includes data on Bretylium Tosylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bretylium Tosylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bretylium Tosylate suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bretylium Tosylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bretylium Tosylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bretylium Tosylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bretylium Tosylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bretylium Tosylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bretylium Tosylate suppliers with NDC on PharmaCompass.
Bretylium Tosylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bretylium Tosylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bretylium Tosylate GMP manufacturer or Bretylium Tosylate GMP API supplier for your needs.
A Bretylium Tosylate CoA (Certificate of Analysis) is a formal document that attests to Bretylium Tosylate's compliance with Bretylium Tosylate specifications and serves as a tool for batch-level quality control.
Bretylium Tosylate CoA mostly includes findings from lab analyses of a specific batch. For each Bretylium Tosylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bretylium Tosylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Bretylium Tosylate EP), Bretylium Tosylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bretylium Tosylate USP).
LOOKING FOR A SUPPLIER?